
Howard A Rockman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8579814/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Seven-transmembrane-spanning receptors and heart function. Nature, 2002, 415, 206-212.	27.8	862
2	Targeting the Receptor-Gq Interface to Inhibit in Vivo Pressure Overload Myocardial Hypertrophy. Science, 1998, 280, 574-577.	12.6	442
3	Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor. Nature, 1995, 374, 272-276.	27.8	431
4	β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. Journal of Clinical Investigation, 2007, 117, 2445-2458.	8.2	405
5	Animal Models of Heart Failure. Circulation Research, 2012, 111, 131-150.	4.5	378
6	Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress. Circulation, 2002, 105, 85-92.	1.6	352
7	Transthoracic Echocardiography in Models of Cardiac Disease in the Mouse. Circulation, 1996, 94, 1109-1117.	1.6	299
8	Regulation of β-Adrenergic Receptor Signaling by S-Nitrosylation of G-Protein-Coupled Receptor Kinase 2. Cell, 2007, 129, 511-522.	28.9	274
9	Mechanism of β-Adrenergic Receptor Desensitization in Cardiac Hypertrophy Is Increased β-Adrenergic Receptor Kinase. Journal of Biological Chemistry, 1997, 272, 17223-17229.	3.4	241
10	β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14555-14560.	7.1	241
11	Dual Inhibition of β-Adrenergic and Angiotensin II Receptors by a Single Antagonist. Circulation, 2003, 108, 1611-1618.	1.6	236
12	From The Cover: Drosophila as a model for the identification of genes causing adult human heart disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1394-1399.	7.1	226
13	Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. Journal of Clinical Investigation, 2006, 116, 1547-1560.	8.2	220
14	Lethal Cardiomyopathy in Mice Lacking Transferrin Receptor in the Heart. Cell Reports, 2015, 13, 533-545.	6.4	213
15	beta-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16284-16289.	7.1	208
16	TRPC1 Channels Are Critical for Hypertrophic Signaling in the Heart. Circulation Research, 2009, 105, 1023-1030.	4.5	202
17	G-Protein–Coupled Receptors in Heart Disease. Circulation Research, 2018, 123, 716-735.	4.5	184
18	Gβγ-dependent Phosphoinositide 3-Kinase Activation in Hearts with in Vivo Pressure Overload Hypertrophy. Journal of Biological Chemistry, 2000, 275, 4693-4698.	3.4	183

#	Article	IF	CITATIONS
19	Phosphoinositide 3-kinase regulates β2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/β-arrestin complex. Journal of Cell Biology, 2002, 158, 563-575.	5.2	178
20	Circulating Exosomes Induced by Cardiac Pressure Overload Contain Functional Angiotensin II Type 1 Receptors. Circulation, 2015, 131, 2120-2130.	1.6	177
21	Manifold roles of β-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9. Science Signaling, 2018, 11, .	3.6	169
22	Agonist-dependent Recruitment of Phosphoinositide 3-Kinase to the Membrane by β-Adrenergic Receptor Kinase 1. Journal of Biological Chemistry, 2001, 276, 18953-18959.	3.4	168
23	Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 1006-1018.	2.6	165
24	β-Arrestin–Biased Agonism of the Angiotensin Receptor Induced by Mechanical Stress. Science Signaling, 2010, 3, ra46.	3.6	163
25	Control of Myocardial Contractile Function by the Level of β-Adrenergic Receptor Kinase 1 in Gene-targeted Mice. Journal of Biological Chemistry, 1998, 273, 18180-18184.	3.4	153
26	β-Arrestin–dependent activation of Ca2+/calmodulin kinase II after β1–adrenergic receptor stimulation. Journal of Cell Biology, 2010, 189, 573-587.	5.2	142
27	Transgenic Mice with Cardiac Overexpression of $\hat{I}\pm 1B$ -Adrenergic Receptors. Journal of Biological Chemistry, 1997, 272, 21253-21259.	3.4	140
28	Protein Kinase A and G Protein-coupled Receptor Kinase Phosphorylation Mediates β-1 Adrenergic Receptor Endocytosis through Different Pathways. Journal of Biological Chemistry, 2003, 278, 35403-35411.	3.4	140
29	Cardiac Overexpression of a G _q Inhibitor Blocks Induction of Extracellular Signal–Regulated Kinase and c-Jun NH ₂ -Terminal Kinase Activity in In Vivo Pressure Overload. Circulation, 2001, 103, 1453-1458.	1.6	130
30	Protein kinase activity of phosphoinositide 3-kinase regulates β-adrenergic receptor endocytosis. Nature Cell Biology, 2005, 7, 785-796.	10.3	125
31	Inhibition of receptor-localized PI3K preserves cardiac β-adrenergic receptor function and ameliorates pressure overload heart failure. Journal of Clinical Investigation, 2003, 112, 1067-1079.	8.2	117
32	Defective Î ² -Adrenergic Receptor Signaling Precedes the Development of Dilated Cardiomyopathy in Transgenic Mice with Calsequestrin Overexpression. Journal of Biological Chemistry, 1999, 274, 22251-22256.	3.4	113
33	Cellular and functional defects in a mouse model of heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H3101-H3112.	3.2	108
34	β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H1001-H1010.	3.2	105
35	Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. Journal of the American College of Cardiology, 2001, 38, 876-882.	2.8	94
36	β-Arrestin Mediates β1-Adrenergic Receptor-Epidermal Growth Factor Receptor Interaction and Downstream Signaling. Journal of Biological Chemistry, 2009, 284, 20375-20386.	3.4	92

#	Article	IF	CITATIONS
37	When 7 transmembrane receptors are not G protein-coupled receptors. Journal of Clinical Investigation, 2005, 115, 2971-2974.	8.2	88
38	Augmentation of Cardiac Contractility Mediated by the Human β ₃ -Adrenergic Receptor Overexpressed in the Hearts of Transgenic Mice. Circulation, 2001, 104, 2485-2491.	1.6	85
39	l² ₁ -Adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H1377-H1386.	3.2	85
40	Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling. Nature Communications, 2017, 8, 1706.	12.8	83
41	Network integration of the adrenergic system in cardiac hypertrophy. Cardiovascular Research, 2004, 63, 391-402.	3.8	81
42	β-Arrestin: A signaling molecule and potential therapeutic target for heart failure. Journal of Molecular and Cellular Cardiology, 2011, 51, 534-541.	1.9	79
43	Restoration of β-Adrenergic Receptor Signaling and Contractile Function in Heart Failure by Disruption of the βARK1/Phosphoinositide 3-Kinase Complex. Circulation, 2005, 111, 2579-2587.	1.6	72
44	Functional Selectivity in Adrenergic and Angiotensin Signaling Systems. Molecular Pharmacology, 2010, 78, 983-992.	2.3	71
45	Differential myocardial gene expression in the development and rescue of murine heart failure. Physiological Genomics, 2003, 15, 105-114.	2.3	70
46	Role of Î ² -adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Review of Cardiovascular Therapy, 2006, 4, 417-432.	1.5	70
47	Biased G Protein–Coupled Receptor Signaling. Circulation, 2018, 137, 2315-2317.	1.6	69
48	Level of β-Adrenergic Receptor Kinase 1 Inhibition Determines Degree of Cardiac Dysfunction After Chronic Pressure Overload–Induced Heart Failure. Circulation, 2005, 111, 591-597.	1.6	65
49	Regulation of myocardial βARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing α1B-adrenergic receptors. Journal of the American College of Cardiology, 2001, 38, 534-540.	2.8	62
50	The two-pore domain potassium channel TREK-1 mediates cardiac fibrosis and diastolic dysfunction. Journal of Clinical Investigation, 2018, 128, 4843-4855.	8.2	62
51	Reduced life span with heart and muscle dysfunction in Drosophila sarcoglycan mutants. Human Molecular Genetics, 2007, 16, 2933-2943.	2.9	61
52	JNK1 is required to preserve cardiac function in the early response to pressure overload. Biochemical and Biophysical Research Communications, 2006, 343, 1060-1066.	2.1	60
53	β-Arrestin1–Biased β ₁ -Adrenergic Receptor Signaling Regulates MicroRNA Processing. Circulation Research, 2014, 114, 833-844.	4.5	60
54	Allosteric Modulation of β-Arrestin-biased Angiotensin II Type 1 Receptor Signaling by Membrane Stretch. Journal of Biological Chemistry, 2014, 289, 28271-28283.	3.4	55

#	Article	IF	CITATIONS
55	Drosophila, Genetic Screens, and Cardiac Function. Circulation Research, 2011, 109, 794-806.	4.5	51
56	Physiologic and cardiac roles of β-arrestins. Journal of Molecular and Cellular Cardiology, 2009, 46, 300-308.	1.9	50
57	Targeted Inhibition of β-Adrenergic Receptor Kinase-1–Associated Phosphoinositide-3 Kinase Activity Preserves β-Adrenergic Receptor Signaling and Prolongs Survival in Heart Failure Induced by Calsequestrin Overexpression. Journal of the American College of Cardiology, 2005, 45, 1862-1870.	2.8	48
58	Enhanced Contractility and Decreased Î ² -Adrenergic Receptor Kinase-1 in Mice Lacking Endogenous Norepinephrine and Epinephrine. Circulation, 1999, 99, 2702-2707.	1.6	46
59	Beta-Arrestin-Mediated Signaling in the Heart. Circulation Journal, 2008, 72, 1725-1729.	1.6	46
60	β-Arrestin mediates the Frank–Starling mechanism of cardiac contractility. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14426-14431.	7.1	46
61	Gene Deletion Screen for Cardiomyopathy in Adult Drosophila Identifies a New Notch Ligand. Circulation Research, 2010, 106, 1233-1243.	4.5	43
62	Dilated cardiomyopathy in transgenic mice expressing a mutant A subunit of protein phosphatase 2A. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1307-H1318.	3.2	41
63	Role of Phosphoinositide 3-Kinase in Cardiac Function and Heart Failure. Trends in Cardiovascular Medicine, 2003, 13, 206-212.	4.9	41
64	G Protein–coupled Receptor Biased Agonism. Journal of Cardiovascular Pharmacology, 2016, 67, 193-202.	1.9	41
65	Mechanoactivation of the angiotensin II type 1 receptor induces βâ€arrestinâ€biased signaling through Gα _i coupling. Journal of Cellular Biochemistry, 2018, 119, 3586-3597.	2.6	39
66	\hat{l}^2 -Adrenergic axis and heart disease. Trends in Genetics, 2001, 17, S44-S49.	6.7	38
67	β-Arrestin mediates oxytocin receptor signaling, which regulates uterine contractility and cellular migration. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E468-E477.	3.5	37
68	β-arrestin 1 regulates β2-adrenergic receptor-mediated skeletal muscle hypertrophy and contractility. Skeletal Muscle, 2018, 8, 39.	4.2	37
69	Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. Current Opinion in Cardiology, 2007, 22, 443-449.	1.8	35
70	Synthetic nanobodies as angiotensin receptor blockers. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20284-20291.	7.1	35
71	Multiple quantitative trait loci modify the heart failure phenotype in murine cardiomyopathy. Human Molecular Genetics, 2003, 12, 3097-3107.	2.9	32
72	Competitive displacement of phosphoinositide 3-kinase from β-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H1754-H1760.	3.2	29

#	Article	IF	CITATIONS
73	Increased myocardial contractility and enhanced exercise function in transgenic mice overexpressing either adenylyl cyclase 5 or 8. Basic Research in Cardiology, 2008, 103, 22-30.	5.9	26
74	<i>β</i> -Arrestin–Biased Allosteric Modulator Potentiates Carvedilol-Stimulated <i>β</i> Adrenergic Receptor Cardioprotection. Molecular Pharmacology, 2021, 100, 568-579.	2.3	24
75	Left Ventricular Functional Assessment in Mice: Feasibility of High Spatial and Temporal Resolution ECG-gated Blood Pool SPECT. Radiology, 2007, 245, 440-448.	7.3	23
76	Cardiomyopathy Is Associated with Ribosomal Protein Gene Haplo-Insufficiency in <i>Drosophila melanogaster</i> . Genetics, 2011, 189, 861-870.	2.9	23
77	G protein-coupled receptor signaling: transducers and effectors. American Journal of Physiology - Cell Physiology, 2022, 323, C731-C748.	4.6	22
78	Cardiac hypertrophy and altered β-adrenergic signaling in transgenic mice that express the amino terminus of β-ARK1. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H2201-H2211.	3.2	21
79	Phosphorylation of Src by phosphoinositide 3-kinase regulates beta-adrenergic receptor-mediated EGFR transactivation. Cellular Signalling, 2016, 28, 1580-1592.	3.6	21
80	β-adrenergic receptor desensitization in cardiac hypertrophy and heart failure. Cell Biochemistry and Biophysics, 1999, 31, 321-329.	1.8	20
81	The β-arrestin-biased β-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12435-12443.	7.1	19
82	β-Arrestin–Biased Angiotensin II Receptor Agonists for COVID-19. Circulation, 2020, 142, 318-320.	1.6	19
83	The role of β-arrestin2-dependent signaling in thoracic aortic aneurysm formation in a murine model of Marfan syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H1516-H1527.	3.2	17
84	Mdm2 regulates cardiac contractility by inhibiting GRK2-mediated desensitization of \hat{I}^2 -adrenergic receptor signaling. JCI Insight, 2017, 2, .	5.0	17
85	The deubiquitinase ubiquitin–specific protease 20 is a positive modulator of myocardial β1-adrenergic receptor expression and signaling. Journal of Biological Chemistry, 2019, 294, 2500-2518.	3.4	17
86	Sensing heart stress. Nature Medicine, 2003, 9, 19-20.	30.7	16
87	Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize β-adrenergic receptor function in heart failure. Vascular Pharmacology, 2006, 45, 77-85.	2.1	16
88	A murine model of increased coronary sinus pressure induces myocardial edema with cardiac lymphatic dilation and fibrosis. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H895-H907.	3.2	11
89	Mapping Angiotensin II Type 1 Receptor-Biased Signaling Using Proximity Labeling and Proteomics Identifies Diverse Actions of Biased Agonists. Journal of Proteome Research, 2021, 20, 3256-3267.	3.7	11
90	Decreased beta-adrenergic responsiveness following hypertrophy occurs only in cardiomyocytes that also re-express beta-myosin heavy chain. European Journal of Heart Failure, 2009, 11, 648-652.	7.1	10

#	Article	IF	CITATIONS
91	Galactokinase Is a Novel Modifier of Calcineurin-Induced Cardiomyopathy in <i>Drosophila</i> . Genetics, 2014, 198, 591-603.	2.9	10
92	Late onset cardiovascular dysfunction in adult mice resulting from galactic cosmic ray exposure. IScience, 2022, 25, 104086.	4.1	9
93	Proximity labeling for investigating protein-protein interactions. Methods in Cell Biology, 2022, , 237-266.	1.1	7
94	An N-ethyl-N-nitrosourea mutagenesis recessive screen identifies two candidate regions for murine cardiomyopathy that map to chromosomes 1 and 15. Mammalian Genome, 2009, 20, 296-304.	2.2	6
95	Methods for the Detection of Altered \hat{l}^2 -Adrenergic Receptor Signaling Pathways in Hypertrophied Hearts. , 2005, 112, 353-362.		4
96	Heart fails without pump partner. Nature, 2011, 477, 546-547.	27.8	4
97	Introduction to the Series on Novel Aspects of Cardiovascular G-Protein-Coupled Receptor Signaling. Circulation Research, 2011, 109, 202-204.	4.5	4
98	Deletion of Siah-interacting protein gene in Drosophila causes cardiomyopathy. Molecular Genetics and Genomics, 2012, 287, 351-360.	2.1	3
99	Role of βâ€Adrenoceptor Desensitization in Heart Failure. Cardiovascular Drug Reviews, 1999, 17, 384-394.	4.1	2
100	The role of G-protein-coupled receptors in heart failure. Drug Discovery Today Disease Mechanisms, 2004, 1, 37-43.	0.8	1
101	Receptor-Signaling Pathways in Heart Failure. , 2005, , 123-143.		0
102	Lessons From Overexpressed Mouse Models. , 2006, , 293-320.		0
103	Receptor Signaling Pathways in Heart Failure: Transgenic Mouse Models. , 2008, , 89-111.		0
104	[beta]1 adrenergic receptor ([beta]1AR)â€epidermal growth factor receptor (EGFR) interaction regulates ERK cellular activity. FASEB Journal, 2008, 22, 723.1.	0.5	0
105	AT1 A Râ€Î²â€∎rrestin signaling confers PPARγ agonistâ€mediated myocyte contractility. FASEB Journal, 2010, 24 586.3.	¹ ,0.5	0
106	Increased intracellular creatine content is not harmful to the mouse heart. FASEB Journal, 2011, 25, 1033.10.	0.5	0
107	Modulating G Protein-Coupled Receptors to Effect Reverse Cardiac Remodeling. , 2013, , 159-177.		0
108	Abstract 274: Carvedilol Stimulated Gαi-β-Arrestin Biased β1 Adrenergic Receptor Signaling. Circulation Research, 2015, 117, .	4.5	0